Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, randomized clinical trial in second line patients comparing the combination of sitravatinib plus a checkpoint inhibitor to docetaxel in patients whose tumors have progressed on prior checkpoint inhibitor therapy

Next Previous
Search
Trial Profile

A Phase III, randomized clinical trial in second line patients comparing the combination of sitravatinib plus a checkpoint inhibitor to docetaxel in patients whose tumors have progressed on prior checkpoint inhibitor therapy

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sitravatinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Mirati Therapeutics

Most Recent Events

  • 06 Nov 2018 According to a Mirati Therapeutics media release, the company plans to begin this trial in the first half of 2019.
  • 26 Oct 2018 New trial record
  • 22 Oct 2018 According to a Mirati Therapeutics media release, this trial is based on guidance received from the FDA in an end of Phase 2 meeting. The trial will include an interim analysis of overall response rate (ORR) as a surrogate endpoint to serve as the basis for potential Subpart H accelerated approval.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top